Videos
GLP-1 Receptor Agonists: Prescribing, Managing, and Sustaining Long-Term Success
Interview With April Watkins, DNP, APRN
Interview With April Watkins, DNP, APRN
05/13/2026
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of EP Lab Digest or HMP Global, their employees, and affiliates.
Interview by Jodie Elrod
In this interview, April Watkins, DNP, APRN, discusses the expanding role of GLP-1 receptor agonists within atrial fibrillation (AF) risk factor modification programs. She shares practical insights on prescribing and managing these therapies, including strategies to support adherence and long-term success, and highlights how advanced practice providers can help integrate GLP-1s into comprehensive AF care to improve patient outcomes and sustain meaningful lifestyle changes.
Clinical Summary
- Atrial fibrillation (AF); GLP-1 receptor agonists (semaglutide, tirzepatide); SELECT trial: 20% reduction in major adverse cardiovascular events (MACE); tirzepatide also indicated for obstructive sleep apnea; targets key AF risk factors—hypertension and obesity.
- Care setting: risk factor modification clinic (Providence Swedish, Ascension): Protocol-driven prescribing since 2022; example patient lost 39 lb over 9 months post-AF ablation, improving risk factors and enabling medication de-escalation.
- Clinical management: Monitor tolerability (nausea, GI effects), baseline labs (BNP, A1C, thyroid), titrate at ~4 weeks; ≥10% weight loss (LEGACY trial) linked to improved AF outcomes and reduced progression.
Reviewed by Jodie Elrod, Managing Editor
Current Issue
May 2026
Volume 26
Issue 5
Stay in the know.
EP Lab Digest Newsletter
